ClinicalTrials.gov
ClinicalTrials.gov Menu

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01665768
Recruitment Status : Active, not recruiting
First Posted : August 15, 2012
Last Update Posted : July 13, 2017
Sponsor:
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : July 2020
  Estimated Study Completion Date : July 2020